# Gujarat Themis to acquire Sanofi anti-TB portfolio for €158 million.

*biotech · news · 2026-04-24 · CNBC TV18*

## Key points

- Gujarat Themis Biosyn will acquire Sanofi's anti-TB and anti-infective brands for €158 million.
- The acquisition covers 13 branded generic products sold in over 55 countries across EMEA regions.
- GTBL will not acquire any manufacturing facilities, legal entities, or employees in the transaction.
- The acquired portfolio's net sales declined from €67 million in FY24 to €62 million in FY25.
- The deal enables GTBL to access regulated and semi-regulated markets and integrate APIs with finished products.

**Companies:** Sanofi, Gujarat Themis Biosyn Ltd.
**Countries:** India, France

[Read the full story on CNBC TV18](https://www.cnbctv18.com/market/gujarat-themis-biosyn-share-price-to-acquire-sanofi-anti-tb-portfolio-for-euro-158-million-ws-el-19892433.htm)

---

Canonical: https://newsio.io/n/57aae2f0-202f-46ba-92df-fbe308b87374/gujarat-themis-to-acquire-sanofi-anti-tb-portfolio-for-158-million-the-deal-valu
Summarized by Newsio from CNBC TV18. https://newsio.io/how-it-works